Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of D-xylose product to preparation of UTI (urinary tract infection) preventing and treating drug

A technology for urinary system infection and xylose is applied in the application field of monosaccharide xylose products in the preparation of drugs for preventing and treating urinary system infection, and achieves the effects of excellent processing characteristics and high safety

Inactive Publication Date: 2018-02-09
TIANJIN MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no literature report on the use of xylose in the prevention and treatment of urinary system infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of D-xylose product to preparation of UTI (urinary tract infection) preventing and treating drug
  • Application of D-xylose product to preparation of UTI (urinary tract infection) preventing and treating drug
  • Application of D-xylose product to preparation of UTI (urinary tract infection) preventing and treating drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Effect of D-xylose on CFT073 infecting bladder epithelial cell 5637 and kidney epithelial cell 786-O

[0029] 1) Take a little bacterial solution from the strain preservation tube, streak and inoculate it on a Luria-Bertani solid plate, cultivate overnight at 37°C.

[0030] 2) Pick a monoclonal colony from the LB solid plate, inoculate it in 5 ml LB liquid medium, and culture overnight at 37°C.

[0031] 3) Take 1 ml of the bacterial solution into a 1.5 ml centrifuge tube, centrifuge at 6000 rpm for 5 minutes to collect the bacterial cells, discard the supernatant, wash with PBS, and resuspend the bacterial cells with the corresponding cell culture medium.

[0032] 4) Set different bacterial MOI values ​​and different D-xylose concentrations to incubate with 5637 and 786-O cells for 2 hours.

[0033] 5) Discard the culture supernatant, wash 5 times with PBS, lyse with 0.2% Triton X-100 for 10 minutes, and collect the lysate.

[0034] 6) The above lysate was serially di...

Embodiment 2

[0037]The role of D-xylose in the invasion of bladder epithelial cells 5637 by UPEC clinical isolate

[0038] 1) Take a little bacterial solution from the strain preservation tube, streak and inoculate it on LB solid plate, culture overnight at 37°C.

[0039] 2) Pick a monoclonal colony from the solid plate, inoculate it in 5 ml LB liquid medium, and culture overnight at 37°C.

[0040] 3) Take 1ml of the bacterial solution into a 1.5 mL centrifuge tube, centrifuge at 6000 rpm for 5 minutes to collect the bacterial cells, discard the supernatant, wash with PBS, and resuspend the bacterial cells with the corresponding cell culture medium.

[0041] 4) 5637 cells were co-incubated with 0.5 mg / ml D-xylose and different UPEC clinical isolates for 2 hours.

[0042] 5) The culture supernatant was discarded, washed 5 times with PBS, lysed with 0.2% Triton X-100 for 10 minutes, and the lysate was collected.

[0043] 6) The above lysate was serially diluted, spread on a non-resistant L...

Embodiment 3

[0046] D-xylose content in urine within a certain period of time after administration of D-xylose in C57BL / 6J mice

[0047] Select C57BL / 6J female mice aged 6-8 weeks, give 100 mg / kg D-xylose orally, collect urine within 0-6 hours, and measure D in urine by phloroglucinol color development -xylose content.

[0048] The results showed that the D-xylose content in urine reached the highest within 1-2 hours after gavage, and D-xylose was basically excreted with urine after 6 hours.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a D-xylose product to preparation of a UTI (urinary tract infection) preventing and treating drug. Cytobiologic experiments and animal experiments prove thatD-xylose can effectively prevent binding of UPEC (uropathogenic Escherichia coli) with bladder cells and nephrocytes, remarkably reduces colonization of UPEC in the urinary bladder of a mouse body and has the effect of preventing and treating UPEC derived UTI.

Description

technical field [0001] The invention belongs to the technical field of application of pharmaceutical products, and relates to the application of monosaccharide xylose products in the preparation of drugs for preventing and treating urinary system infections. Background technique [0002] Urinary tract infections (UTI, urinary tract infections) is one of the most common bacterial infections, urinary tract infections caused by pathogenic bacteria can lead to acute simple cystitis, acute simple pyelonephritis, complicated urinary tract infections, recurrent urinary tract infections and other clinical common urinary system infectious diseases. It has been reported that approximately 40% of women and 12% of men will experience at least one symptomatic UTI in their lifetime, and 10% of these women will have a recurrent infection within 6-12 months of infection. Statistics show that there are more than ten million cases of urinary system infection every year in the world. Urinary...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7004A61P13/00A61P31/04
CPCA61K31/7004Y02A50/30
Inventor 王荃李晓
Owner TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com